Navigation Links
Novelda Appoints Alf-Egil Bogen as Chief Executive Officer to Lead the Company to the Next Level
Date:8/22/2013

OSLO, Norway, Aug. 22, 2013 /PRNewswire/ -- Novelda, the provider of Nanoscale Impulse Radar solutions, announces the appointment of Alf-Egil Bogen as Chief Executive Officer. Bogen, one of the inventors of the successful AVR Microcontroller, has been in the semiconductor industry for over 20 years and most recently served as CMO for Atmel Corporation where he was based in San Jose, California and as CMO for Energy Micro, assisting the sale of the company to Silicon Labs in Texas.

(Photo: http://photos.prnewswire.com/prnh/20130822/PH67741-a )

(Logo: http://photos.prnewswire.com/prnh/20130822/PH67741LOGO-b )

"I am very excited to work for Novelda. Their proprietary CMOS chips for radar solutions open up a new world of opportunities. Not only can it see objects, but it can also see through them!" says Alf-Egil Bogen. "I have been on their board for a while, and also invested money in the company, so I really believe in the company. Dag Wisland and his team have done a great job and established a very impressive customer base for this product. I am looking forward to working with Dag to take Novelda to next level," he continues.

Dag T. Wisland will be the President for the company and will focus more on R&D moving forward. Dag is one of the founders of Novelda and says this about getting Bogen on board: "Alf-Egil Bogen has the combination of technical and business experience we need to take the next step. His long semiconductor experience and the ability to get good results are very impressive. The entire team is excited about this, and we look forward to working with him."

"Our strategy for the company involves a strong focus on turnkey solutions for our OEM customers. We want to help them in the design of amazing radars for medical, building automation, robots and many other applications. I am also proud of the relationship with Samsung Thales to search for land mines. If we can help saving lives with our technology that will feel very right," Bogen finishes.

ABOUT NOVELDA AS

Novelda AS is a privately held, R&D driven, Semiconductor Company, based in Norway and specializing in nanoscale wireless low-power technology for ultra-high resolution impulse radar.

The Novelda Impulse Radar is a complete CMOS radar system integrated on a single chip: a sensor for human vital sign monitoring, personal security, environmental monitoring, industrial automation and robotics. In addition to being an alternative to, or complementing existing technologies such as video, ultrasound and infrared sensors, it opens up for new application areas due to its speed and resolution, and its ability to "see through" obstacles.

Novelda was founded in 2004 as a spinout from the University of Oslo, and there is a strong Research & Development partnership with the university. www.novelda.no

High-resolution image:

Press Release Contact:   
President Dag Wisland: dag(at)novelda.no 
CMO Aage Kalsaeg: aage(at)novelda.no

Read more news from Novelda.               


'/>"/>
SOURCE Novelda AS
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. State-of-the-Art Novelda NVA6000 Impulse Radar Transceiver Finds Widespread Appeal and Applications
2. Samsung Thales signs Development Agreement with Novelda
3. Arecor Appoints Dr. Sarah Howell as Chief Operating Officer
4. Elsevier / MEDai Appoints Tom Zajac as New President
5. Immune Design Corp. Appoints Wayne R. Gombotz, Ph.D. as Chief Development Officer
6. Hybrid Fuels, Inc. Appoints Industry Expert as New CEO
7. BioStorage Technologies Appoints New Member to Board of Directors
8. Selexis SA Appoints Yemi Onakunle as Vice President of Strategic and Market Development
9. Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director
10. PuraMed BioScience, Inc. Appoints Sue A. Baacke, CPA, as CFO
11. PAREXEL Appoints Former Senior FDA Official David Elder to Global Team of Strategic Compliance Experts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... findings on what they believe could be a new and helpful biomarker for ... research. Click here to read it now. , Biomarkers are components ...
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of 8.5 ... end machines that use the more unconventional z-dimension of 20mm. Z-dimension or ... the cuvette holder. , FireflySci has developed several Agilent flow cell product lines ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
Breaking Biology Technology:
(Date:6/2/2016)... 2016 The Department of Transport Management ... 44 million US Dollar project, for the , ... Personalization, Enrolment, and IT Infrastructure , to ... and implementation of Identity Management Solutions. Numerous renowned international vendors ... Decatur was selected for the most compliant and ...
(Date:5/24/2016)... care by providing unparalleled technology to leaders of the medical imaging industry.  As such, ... to the range of products distributed by Ampronix. Photo - http://photos.prnewswire.com/prnh/20160524/371420 ... ... ... With ...
(Date:5/9/2016)... 9, 2016 Elevay is currently ... expanding freedom for high net worth professionals seeking travel ... globally connected world, there is still no substitute for ... duplicate sealing your deal with a firm handshake. This ... taking advantage of citizenship via investment programs like those ...
Breaking Biology News(10 mins):